Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth with Inflammatory Bowel Disease by Stapersma, L. (Luuk) et al.
Illness Perceptions and Depression Are Associated
with Health-Related Quality of Life in Youth with Inflammatory
Bowel Disease
Luuk Stapersma1 & Gertrude van den Brink2 & Jan van der Ende1 & Alexander G. Bodelier3 & Herbert M. van Wering4 &
Pamela C. W. M. Hurkmans3 & M. Luisa Mearin5 & Andrea E. van der Meulen–de Jong6 & Johanna C. Escher2 &
Elisabeth M. W. J. Utens1,7,8
Published online: 10 June 2019
# The Author(s) 2019
Abstract
Background In youth with inflammatory bowel disease (IBD), health-related quality of life (HRQOL) has been shown to be
affected by individual disease factors and specific psychological factors. The innovative aim of this study is to examine the
combined impact of psychological factors (illness perceptions, cognitive coping, anxiety, and depression) on HRQOL, over and
above the associations of demographic and disease factors with HRQOL in youth with IBD.
Method Data on clinical disease activity, illness perceptions, cognitive coping, anxiety, depression, and HRQOL were prospec-
tively collected in 262 consecutive youth (age 10–20, 46.6% male) with confirmed IBD. Multiple linear regression analyses
tested the associations of demographic, disease, and psychological variables with HRQOL in separate groups for Crohn’s disease
(CD; N = 147) and ulcerative colitis and IBD unclassified (UC/IBD-U; N = 115), using age-specific validated instruments.
Results In both disease groups, more negative illness perceptions (ß = − .412; ß = − .438, p < .001) and more depression (ß =
− .454; ß = − .279, p < .001) were related to lower HRQOL. In the UC/IBD-U group, more anxiety was related to lower HRQOL
(ß = − .201, p = .001). The model with the psychological variables explained a large and significant amount of variance in both
groups: 74% and 83%, respectively (p < .001).
Conclusion In 10–20-year-old IBD patients, negative illness perceptions and depression were significantly and more strongly
associated with lower HRQOL than demographic and disease factors. Thus, it is important to integrate psychological factors in
the treatment for IBD patients. To improve HRQOL in young IBD patients, psychological interventions should be targeted at
negative illness perceptions and depression.
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Introduction
Inflammatory bowel disease (IBD) is a disabling chronic gas-
trointestinal condition, with two predominant subtypes:
Crohn’s disease (CD) and ulcerative colitis (UC). In up to
25% of patients, IBD starts in late childhood or adolescence
[1–3]. The designation IBD unclassified (IBD-U) is used for
patients in which it is not (yet) possible to make a distinction
between CD and UC. IBD is characterized by periods of clin-
ical disease activity and remission and presents with
* Elisabeth M. W. J. Utens
e.utens@erasmusmc.nl
1 Department of Child and Adolescent Psychiatry/Psychology,
Erasmus MC-Sophia Children’s Hospital, Wytemaweg 8, 3015
CN Rotterdam, The Netherlands
2 Department of Pediatric Gastroenterology, Erasmus MC-Sophia
Children’s Hospital, Rotterdam, The Netherlands
3 Department of Gastroenterology, Amphia Hospital,
Breda, The Netherlands
4 Department of Pediatrics, Amphia Hospital, Breda, The Netherlands
5 Department of Pediatrics, Leiden University Medical Center,
Leiden, The Netherlands
6 Department of Gastroenterology,
Leiden University Medical Center,
Leiden, The Netherlands
7 Research Institute of Child Development
and Education, University of Amsterdam,
Amsterdam, The Netherlands
8 Academic Center for Child Psychiatry the Bascule/Department of
Child and Adolescent Psychiatry, Academic Medical Center,
Amsterdam, The Netherlands
International Journal of Behavioral Medicine (2019) 26:415–426
https://doi.org/10.1007/s12529-019-09791-6
symptoms such as abdominal pain, bloody diarrhea, fatigue,
and weight loss [4]. In adolescence, growth failure and de-
layed pubertal development is common, specifically in
Crohn’s disease. The adolescent life phase is characterized
by development on several domains (biological, psychologi-
cal, social, cognitive, academic). Having a chronic disease
such as IBD can affect all these domains, for example, not
only becoming more independent from parents, developing
long-term friendships, starting secondary education, forming
an own identity, but also experimenting with alcohol and
drugs, seeking and finding a (side) job, and having romantic
relationships. The teenage years are a crucial period of transi-
tion from childhood to young adulthood [5]. IBD and its med-
ical treatment may severely impact psychosocial functioning:
health-related quality of life (HRQOL) in children and adoles-
cents (further referred to as youth) with IBD is significantly
lower than in healthy peers [6, 7]. Furthermore, high preva-
lence rates varying from 20 to 50% for anxiety and depression
are found in these patients [8–11]. A recent meta-analysis in
children and adolescents showed pooled prevalence rates for
anxiety and depressive symptoms of 15% and for anxiety and
depressive disorders of 3–4% [12].
Other psychological factors are also important to consider
in patients with IBD, such as illness perceptions and coping,
because these have been shown to be related to psychosocial
outcomes (such as HRQOL, general functioning or adjust-
ment to IBD). Illness perceptions refer to the cognitive and
emotional representations a patient forms about his or her
disease [13]. These representations cover several dimensions,
i.e., consequences (the expected effects of the disease), time-
line (expectations about the duration of the disease), cause
(thoughts about the cause of the disease), controllability (the
extent to which the individual believes he or she can control
the disease with or without treatment), identity (how the indi-
vidual describes the symptoms and perceives as part of the
disease), concern (worries about the disease), and emotions
(the emotional response to the disease) [13, 14]. Coping refers
to intentional efforts to regulate negative emotions in response
to harm, threat, or challenges [15, 16] in this study dealing
with IBD. Coping encompasses both cognitive and behavioral
regulation. Cognitive coping is implicated in the etiology and
the maintenance of anxiety and depression [17, 18] and is
therefore important as well in studying youth with IBD.
The common sense model (CSM) is a model to describe the
relationships between disease characteristics, illness percep-
tions, coping, and anxiety, depression, and HRQOL, original-
ly developed by Leventhal and Diefenbach [13]. In this mod-
el, illness characteristics (such as clinical disease activity) lead
to certain thoughts about the illness, the so-called illness per-
ceptions of a patient. These illness perceptions influence the
type of coping the patient uses to deal with his/her symptoms.
Together, these factors lead to positive or negative illness out-
comes, for example, anxiety, depression, or HRQOL. In
patients with IBD, several relationships have been found be-
tween these variables, mostly in adults. Below it will be ex-
plicitly mentioned if studies were conducted in youth with
IBD. For example, more clinical disease activity has been
found to be associated with more anxiety and depression sep-
arately [19, 20]. Previous studies have also demonstrated a
relationship between clinical disease activity and HRQOL,
with a mediating role for anxiety and depressive symptoms
[19, 21]. Furthermore, negative illness perceptions are associ-
ated with lower HRQOL in adults with IBD [22] and also with
more psychological problems in youth with IBD [23]. Coping
was associated with anxiety and depression [24] or adjustment
to IBD [25] in adults and found as predictor of depression in
youth with IBD as well [26].
Unfortunately, very little is known on how all the fac-
tors described above together affect health outcomes,
more specifically HRQOL in young IBD patients. Only
a few studies examined several psychological factors si-
multaneously. In adults, illness perceptions [27] and cop-
ing [24] have been reported to impact the relationship
between clinical disease activity on HRQOL. Recently,
Van Tilburg et al. [28] showed in adolescents with IBD
that patient-reported disability (as outcome) was associat-
ed not only with clinical disease activity but also with a
combined latent construct ‘psychological factors’ (includ-
ing coping, pain beliefs, anxiety, and depression).
However, they did not control for demographic factors
(gender, age, socioeconomic status) and did not include
other disease factors, such as disease type and disease
duration. In addition, there is some evidence that these
disease factors are associated with HRQOL [20, 29, 30]
and with anxiety and/or depression as well [23, 31].
Moreover, because the authors used a combined psycho-
logical construct, their findings provide no insight on
which psychological factors in particular psychological
interventions for youth with IBD should focus.
The complex interplay between clinical disease activity,
illness perceptions, coping, anxiety, and depression makes it
challenging to attune both the medical and psychological
treatment to the individual needs of IBD patients to improve
their HRQOL. The surplus value of the present study in a
cohort of youth with IBD is that it aims to clarify the associ-
ation of a combination of psychological factors (illness per-
ceptions, cognitive coping, anxiety, and depression) with
HRQOL, over and above demographic and disease factors.
By selecting the 10–20-year age range, we cover the period
of transition from childhood to young adulthood. More spe-
cific insight on how psychological factors are associated with
HRQOL in these vulnerable youth can offer guidance on
which factors psychological interventions should focus.
Ultimately, with tailored psychological interventions, the
course of the IBD and of possible psychological problems
may be positively affected. We hypothesize that clinical
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disease activity is negatively associated with HRQOL.
Furthermore, we hypothesize that psychological factors (i.e.,
illness perceptions, cognitive coping, anxiety, and depression,
when tested simultaneously) are associated with HRQOL,
even after controlling for clinical disease activity and other
demographic and disease factors.
Materials and Methods
Design
The present cross-sectional cohort study is based on a large
patient sample (N = 374), completing the baseline assessment
of a multicenter randomized controlled trial (RCT), investigat-
ing a disease-specific cognitive behavioral therapy in youth
with IBD and symptoms of anxiety and/or depression (trial
registration number: NCT02265588, see also Van den Brink
and Stapersma et al. [32]). In the current study, only data from
patients aged 10–20 years were used (N = 262).
Inclusion criteria were as follows: (1) age 10 to 20 years
and (2) diagnosis of IBD, according to the consensus criteria
[33] [34, 35].
Exclusion criteria were as follows: (1) intellectual disabil-
ity; (2) current treatment for mental health problems (pharma-
cological and/or psychological); (3) insufficient mastery of the
Dutch language; (4) a diagnosis of selective mutism, bipolar
disorder, schizophrenia, autism spectrum disorder, obsessive-
compulsive disorder, posttraumatic or acute stress-disorder, or
substance use disorder; (5) cognitive behavioral therapy in the
past year (at least eight sessions); and (6) participation in an-
other intervention study.
Procedure
Consecutive patients and their parents were recruited between
October 2014 and September 2016 from the outpatient clinic
in two academic hospitals and four community hospitals in the
Southwest region of the Netherlands. Patient information was
given, and written informed consent was requested in all pa-
tients and, if applicable, their parents or caregivers. Patients
(and parents), who consented to participate, received an e-mail
with a link to online questionnaires. Clinical disease activity
was scored by the (pediatric) gastroenterologist around the
time of inclusion (i.e., within approximately a month around
the time of inclusion, median = 3.42 weeks).
Measures
Control Variables
Gender, age, disease type, and disease duration of the pa-
t ients were der ived from thei r medical record.
Socioeconomic status (SES) was determined using the oc-
cupational level from the parents or, if they lived on their
own, patients themselves. Using the standard coding sys-
tem of Statistics Netherlands ([36]), occupations were cat-
egorized in low, middle, and high. For gender and SES,
dummy variables were created to use in the analyses.
Clinical disease activitywas assessed by two validated clin-
ical disease activity instruments. For CD, the short Pediatric
Crohn’s Disease Activity Index (sPCDAI) and, for UC, the
Pediatric Ulcerative Colitis Activity Index (PUCAI) were used.
The sPCDAI comprises six items on medical history (abdomi-
nal pain, stools), well-being, physical examination (abdomen),
weight, and extra-intestinal manifestations [37]. Scores range
from 0 to 90 points [38]. The PUCAI comprises six items on
abdominal pain, rectal bleeding, stool frequency and consisten-
cy, and activity level. Scores range from 0 to 85.
Psychological Factors
Illness perceptions were assessed by the Brief Illness
Perceptions Questionnaire (B-IPQ; [14, 39]). This 9-item
self-report questionnaire assesses cognitive and emotional
representations of illness, covering eight dimensions: conse-
quences, timeline, personal control, treatment control, identi-
ty, concern, emotions, and understanding. All dimensions are
scored on an 11-point Likert-scale (0: not at all–10: very
much/severely). A higher score represents more negative ill-
ness perceptions. Good test–retest reliability and concurrent
validity have been found [14], and the B-IPQ has been used
before in adolescents with IBD [40]. Internal consistency
(Cronbach’s alpha) for the current sample was .81 in the CD
group and .81 in the UC/IBD-U group.
Cognitive coping was measured with the Cognitive
Emotion Regulation Questionnaire (CERQ). This self-
report scale consists of 36 items, scored 1 to 5 points,
with nine subscales (e.g., self-blame, acceptance, putting
into perspective, positive refocusing, positive reappraisal,
and catastrophizing). These scales are divided into two
domains: adaptive cognitive coping (e.g., positive reap-
praisal, putting in perspective) and maladaptive cognitive
coping (e.g., self-blame, catastrophizing). A higher score
indicates more use of a particular coping style. Good re-
liability and construct validity have been found [41]. Both
adaptive coping and maladaptive coping were used as
variable in the analyses. For adaptive cognitive coping,
internal consistency was .90 in the CD group and .93 in
the UC/IBD-U group. For maladaptive cognitive coping,
internal consistency was .88 in the CD group and .90 in
the UC/IBD-U group.
Anxiety was assessed using the 69-item self-report ques-
tionnaire Screen for Child Anxiety Related Disorders
(SCARED). The SCARED contains five subscales: general
anxiety disorder, separation anxiety disorder, specific phobia,
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panic disorder, and social phobia, rated on a 3-point scale (0–
2: total score 0–138). Satisfactory reliability and validity have
been reported [42]. The cutoffs for elevated anxiety were total
score ≥ 26 for boys, ≥ 30 for girls, or subscale score ≥ 8 [43].
These were only used to decide whether patients had elevated
anxiety, i.e., could be included in the RCT. Internal consisten-
cy for the current sample was .95 in the CD group and .94 in
the UC/IBD-U group.
Depression was assessed using the Child Depression
Inventory (CDI, for ages 10–17) and the Beck
Depression Inventory, second version (BDI-II, for ages
18–20). The CDI is a 27-item self-report scale (0–2, total
score 0–54). Good reliability and validity have been
established. A CDI score of 13 or higher reflected elevat-
ed depression [44]. The BDI-II is a 21-item self-report
scale (0–3, total score 0–63). It has excellent reliability
and good to excellent validity. A BDI-II score of 14 or
higher reflected elevated symptoms of depression [45].
The cutoffs for the CDI and BDI-II were only used to
decide whether patients had elevated depression, i.e.,
could be included in the RCT. For the CDI, internal con-
sistency was .85 in the CD group and .86 in the UC/IBD-
U group. For the BDI-II, internal consistency was .91 in
the CD group and .84 in the UC/IBD-U group. To be able
to combine patients of all ages within the disease groups,
depression scores were created a Z-score for depression
using either the CDI or the BDI-II (depending on age).
Health-related quality of life was assessed by the IBD-
specific self-report IMPACT-III, which covers six do-
mains: IBD-related symptoms, systemic symptoms, emo-
tional functioning, social functioning, treatment related
concerns, and body image [46]. The 35 items are scored
(1–5; total score 35–175). Good psychometric properties
have been found [47]. The total score was used, and a
higher total score indicates better HRQOL. Although the
IMPACT-III originally was designed for youth up to
18 years, we also used it for the patients of 19 and
20 years. This allowed us to combine all patients in to
one group for each disease type. This was substantiated
by excellent internal consistency in both disease groups:
.93 in the CD group and .94 in the UC/IBD-U group.
Statistical Analyses
To test whether the associations of demographic, disease
and psychological factors with HRQOL are different for
CD than for UC/IBD-U, multiple linear regression analy-
ses were performed for the two disease groups separately:
CD (N = 147) and UC/IBD-U (N = 115). UC and IBD-U
were combined, since the group with IBD-U patients was
quite small (N = 18), IBD-U often resembles UC more than
CD [48], and IBD-U has often a similar treatment approach
as UC [49]. All variables were continuous, except for
gender and SES. For these variables, dummy variables
were included in the analyses. The abovementioned cutoffs
for the SCARED, CDI, and BDI-II were only used to de-
termine the proportion of patients with elevated anxiety or
depressive symptoms. For the remaining questionnaires,
no cutoffs were used.
The multiple linear regression analyses were run with
two blocks/models, using HRQOL as outcome. In the first
block, the demographic and disease variables (gender,
age, disease duration, SES, and clinical disease activity)
were entered simultaneously in the first regression model.
In the second block, the psychological factors (illness
perceptions, cognitive coping, anxiety, and depression)
were added simultaneously to the variables entered in
the first block. To account for missing values, multiple
imputation with chained equations was applied using
SPSS (m = 15 for approximately 15% of missing data;
[50]). As a sensitivity analysis, we also performed a com-
plete case analysis (N = 116; N = 104 for the CD and UC/
IBD-U groups, respectively) to see whether the multiple
imputations had an effect on the results. A p value of
< .05 was considered significant. SPSS Version 24 was
used for the analyses (IBM Corp. Released 2016. IBM
SPSS Statistics for Windows, Version 24.0. Armonk,
NY: IBM Corp). A statistician (JE) supported and advised
in analyzing and interpreting the data and results.
Ethical Considerations
This study was performed conform the Declaration of
Helsinki and approved by the Institutional Review Board of
the Erasmus MC and of each participating center.
Results
Patient Characteristics
In total, 552 patients (aged 10–25 years) were invited for
a randomized controlled trial (RCT) and 382 agreed to
participate (response rate = 69%). Eight patients had in-
complete data. From the final 374 youth, 262 were aged
10–20 years and were included in the current study.
Demographic, disease, and psychological characteristics
are presented in Table 1. In disease groups (CD and UC/
IBD-U), the percentage of patients with active disease
(mild-moderate-severe) was 31.3% and 30.4%, respective-
ly. Overall, 50% of the patients had elevated anxiety,
17.9% had elevated depression, and 16.8% had both.
For HRQOL, illness perceptions, and cognitive coping,
no cutoffs are available; so means with ranges are provid-
ed in Table 1.
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Influence of Demographic, Disease, and Psychological
Variables on HRQOL; Results of Multiple Linear
Regression Analyses per Disease Group
In Tables 2 and 3, the standardized estimates, their sig-
nificance, and the proportion of explained variance for
each regression model (model 1 with demographic and
disease factors and model 2 with psychological factors
added) in the two disease groups are provided. Results
are presented from the analyses on the imputed datasets.
Results from the complete case analyses were similar
(data not shown).
As is seen in Table 2, in the CD group (N = 147), female
gender and clinical disease activity were significantly associ-
ated with HRQOL in the first model, explaining 37% of the
variance in HRQOL. After adding the psychological factors,
clinical disease activity (ß = − .170, p = .001), more negative
illness perceptions (ß = − .412, p < .001), and more depressive
symptoms (ß = − .454, p < .001) were associated with lower
HRQOL. The second model explained 74% of the variance in
HRQOL, with a significant change in explained variance (R2
change = 37%, p < .001).
In the UC/IBD-U group (N = 115), female gender, age,
disease duration, and clinical disease activity were significant-
ly associated with HRQOL in the first model, explaining 32%
of the variance in HRQOL. After adding the psychological
factors, female gender (ß = − .101, p = .022), lower age (ß =
− .193, p < .001), shorter disease duration (ß = .087, p = .045),
more negative illness perceptions (ß = − .438, p < .001), more
anxiety symptoms (ß = − .201, p = .001), and more depressive
symptoms (ß = − .279, p < .001) were associated with lower
HRQOL. The second model explained 83% of the variance,
with a significant change in explained variance (R2 change =
51%, p < .001).
Table 1 Demographic and disease characteristics of total sample of IBD patients (10–20 years)
Group Total
CD UC/IBD-U
N 147 115 262
Demographic characteristics
Age (years), mean (SD) 17.19 (2.52) 16.15 (2.98) 16.74 (2.77)
Male (%) 50.3 41.7 46.6
SES (%)a Low 17.7 13.0 15.6
Middle 32.7 40.9 36.3
High 38.1 43.5 40.5
Disease characteristics
Disease type (%) CD 100 0 56.1
UC 0 84.3 37.0
IBD-U 0 15.7 6.9
Age at diagnosis (years), mean (SD) 14.25 (3.02) 13.18 (3.97) 13.78 (3.50)
Disease duration (years), median (IQR) 2.26 (0.97–4.39) 1.90 (0.62–4.73) 2.03 (0.81–4.56)
Active disease (%)b 31.3 30.4 30.9
Psychological characteristics
Elevated anxiety symptoms (%)c 49.7 50.4 50.0
Elevated depressive symptoms (%)c 15.6 20.9 17.9
Elevated anxiety and depression (%)c 14.3 20.0 16.8
HRQOL, mean (range) 143.36 (76–174) 141.91 (82–173) 142.72 (76–174)
Illness perceptions, mean (range) 34.75 (3–69) 36.69 (9–70) 35.63 (3–70)
Adaptive cognitive coping, mean (range) 57.67 (20–92) 55.72 (21–97) 56.78 (20–97)
Maladaptive cognitive coping, mean (range) 25.05 (16–59) 25.12 (16–56) 25.08 (16–59)
SD standard deviation, SES socioeconomic status, CD Crohn’s disease, UC ulcerative colitis, IBD-U inflammatory bowel disease unclassified, IQR
interquartile range, HRQOL health-related quality of life, sPCDAI short Pediatric Crohn’s Disease Activity Index, PUCAI Pediatric Ulcerative Colitis
Activity Index, SCARED Screen for Child Anxiety Related Emotional Disorders, CDI Child Depression Inventory, BDI-II Beck Depression Inventory,
Second edition
a Not for all patients SES was available: CD N = 130, UC/IBD-U N = 112. Total group N = 242
b Scored above cutoff for active disease on sPCDAI (≥ 10 points) or PUCAI (≥ 10 points)
c Scored above cutoff on SCARED (anxiety), CDI (depression; 10–17 years) and/or BDI-II (depression 18–20 years)
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Discussion
This study examined the influence of psychological factors on
HRQOL over and above the influence of demographic and dis-
ease factors in youth with IBD and analyzed the results
separately for CD and UC/IBD-U. Partly in line with our first
hypothesis, in the first model, without the psychological factors
included, female gender and clinical disease activity were signif-
icantly associated with HRQOL, as were age and disease dura-
tion only in the UC/IBD-U group. However, when adding a
Table 2 Influence of
demographic, disease, and
psychological variables on
HRQOL; results of multiple
linear regression analysis—CD
group (N = 147)
Model 1 Model 2
ß SE ß p value ß SE ß p value
Block 1
Gender Male
Female − .230 .072 .002* − .055 .051 .283
Age − .075 .077 .330 − .054 .056 .330
SES Low
Middle .029 .098 .768 .070 .069 .315
High .051 .097 .600 − .042 .067 .533
Disease duration .123 .072 .086 .064 .049 .193
Clinical disease activity − .482 .071 < .001* − .170 .053 .001*
Block 2
Illness perceptions − .412 .063 < .001*
Adaptive cognitive coping .012 0.49 .803
Maladaptive cognitive coping .018 .058 .759
Anxiety .019 .077 .801
Depression − .454 .077 < .001*
R2 (CI), p value .37 (.24–.49), p < .001* .74 (.65–.80), p < .001*
SE standard error, SES socioeconomic status, CI confidence interval
* significant with p < .05
Table 3 Influence of
demographic, disease, and
psychological variables on
HRQOL; results of multiple
linear regression analysis—UC/
IBD-U group (N = 115)
Model 1 Model 2
ß SE ß p value ß SE ß p value
Block 1
Gender Male
Female − .276 .081 .001* − .101 .044 .022*
Age − .298 .082 < .001* − .193 .045 < .001*
SES Low
Middle − .130 .126 .302 − .033 .066 .619
High − .101 .126 .424 − .047 .067 .483
Disease duration .201 .083 .015* .087 .044 .045*
Clinical disease activity − .289 .081 < .001* − .066 .046 .156
Block 2
Illness perceptions − .438 .056 < .001*
Adaptive cognitive coping .036 .046 .156
Maladaptive cognitive coping − .029 .052 .584
Anxiety − .201 .060 .001*
Depression − .279 .061 < .001*
R2 (CI), p value .32 (.18–.46), p < .001* .83 (.76–.88), p < .001
SE standard error, SES socioeconomic status, CI confidence interval
* significant with p < .05
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combination of all psychological factors simultaneously in the
second model, the influence of demographic and disease factors
was reduced. Subsequently, illness perceptions and depression
were associated with HRQOL in youth with IBD, even when
controlling for demographic and disease factors. More negative
illness perceptions and more depression were associated with a
lower HRQOL, in both the CD group and the UC/IBD-U group.
A difference between the disease groups was that, in the UC/
IBD-U group, anxiety was associated with HRQOL as well.
Most importantly, adding the psychological factors resulted in
a significant increase in the proportion of explained variance,
from approximately 35% by the first model to 74–83% by the
secondmodel, in both groups. This high proportion of explained
variance underlines the importance of psychological factors con-
tributing to HRQOL in patients with IBD.
These results provide insight in which psychological fac-
tors play a role in youth with IBD. Consistently in the two
disease groups, negative illness perceptions and depression in
particular prove their significant role, whereas cognitive cop-
ing was not associated with HRQOL. This was also found in
previous studies, which reported that illness perceptions and
depression were associated with disease outcomes [22, 28].
Therefore, we recommend to pay attention to these factors
when treating patients. Our results suggest that in youth with
UC/IBD-U, anxiety should be considered as well.
There are several explanations for only finding an associa-
tion between anxiety and HRQOL in youth with UC/IBD-U.
Firstly, the nonsignificant relationship between anxiety and
HRQOL in youth with CD cannot be explained by a differ-
ence in the prevalence of elevated anxiety symptoms between
the CD and UC/IBD-U groups (49.7% versus 50.4%).
Secondly, one might postulate that anxiety is not strongly
related to HRQOL in youth with IBD. Although we found a
high prevalence of anxiety symptoms in the current sample
(see Table 1 and [31]), the presence of anxiety symptoms as
such may not have to impact the HRQOL of youth with CD.
In children and adolescents, the available studies did not show
evidence for differences between CD and UC [23], but Sarid
et al. [51] showed worse psychosocial outcomes in patients
with UC [27, 52]. Thirdly, anxiety and depression are highly
comorbid, have overlapping symptoms, and anxiety is consid-
ered a precursor of depression [53, 54]. So anxiety may have
played a role in preceding depressive symptoms in these pa-
tients. It is possible that anxiety and depression both explained
variance in HRQOL, but that depression is more strongly
related to HRQOL and therefore diminished the relationship
between anxiety and HRQOL in the patients with CD. More
research is needed to unravel the interplay between anxiety
and depression in youth with IBD. In their benchmark review,
Cummings et al. [55] describe several pathways for the anxi-
ety and depression comorbidity in children and adolescents.
They also stress the importance of studying specific anxiety
disorders for their comorbidity with depression. In IBD, very
few studies tested specific anxiety problems (e.g., [11]). As a
result, to our knowledge, there are no studies that investigated
how specific anxiety problems are related to depressive symp-
toms in patients with IBD. Fourthly, in adults, several studies
reported on the relationship between anxiety and HRQOL in
both patients with CD and UC [56, 57]. Anxiety might be
more impairing for adults with IBD than for youth with
IBD, since adults may have to deal with more disease-
related anxieties and worries concerning their daily and social
functioning (impact of IBD on employment, career perspec-
tives, income, finding a sexual partner, starting a family, etc.).
Lastly, anxiety symptomsmay be IBD-specific, i.e., anxiety or
worries surrounding their IBD symptoms (e.g., bloody stools,
the necessity of a stoma or surgery). These worries are often
exorbitant to the actual context but can have a negative impact
[58, 59]. More specifically, higher IBD-specific anxiety was
associated with lower HRQOL in youth with both CD and UC
[58]. However, we are not aware of studies that examined
differences between CD and UC with respect to IBD-
specific anxiety in youth. Perhaps, youth with UC/IBD-U ex-
perience different IBD-specific worries than youth with CD,
for example, since youth with UC/IBD-U more often have
alarming bloody stools than youth with CD.
Although the CSM postulates that coping is an important
factor, in our study, cognitive coping was not significantly
related to HRQOL, when simultaneously added to the model
with the other psychological factors. Cognitive coping may
not be related to HRQOL in IBD patients, as was also found in
earlier studies examining individual psychological factors [27,
52]. This is in contrast with the results of a review including a
wide range of illnesses in adults, which found that coping was
a stronger predictor for health outcomes than illness percep-
tions [60]. Perhaps, coping plays a different role in IBD than
in other illnesses. On the other hand, the type of coping may
be of importance, since we only tested cognitive coping styles
(and not for example behavioral). However, the results of two
adult IBD studies including problem-focused and emotion-
focused coping are mixed [61, 62] and therefore do not sup-
port this explanation completely.
Comparing the results between patients with CD and
UC/IBD-U showed differences in the second model: a
significant association of clinical disease activity with
HRQOL in the CD group and a significant association
of gender, age, and disease duration with HRQOL in de
UC/IBD-U group. Most likely, these differences cannot be
explained by differences between the two groups, since
the groups were similar with respect to the percentages
of active disease, males versus females and the disease
duration (see Table 1). Only in the CD group, clinical
disease activity was associated with HRQOL, even after
adding the psychological factors to the model. To our
knowledge, in youth, no studies have specifically exam-
ined differences between CD and UC with respect to the
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relationship between clinical disease activity and
HRQOL. Patients with CD have a more heterogeneous
clinical presentation and are affected by growth failure,
more often than patients with UC and IBD-U [1]. The
heterogeneous clinical presentation and growth failure
can lead to a lower HRQOL. A recent review of
Knowles et al. [63] showed that HRQOL was significant-
ly lower for patients with active disease, although no in-
formation was provided about differences between CD
and UC/IBD-U. In children and adolescents with IBD
(both CD and UC), some studies have shown that clinical
disease activity remained associated with HRQOL, even
when anxiety/depression [19, 21, 64] and parental stress
[64, 65] were included as mediators. It was therefore not
tested, as in our study, what the influence is of demo-
graphic, disease, and psychological factors on the rela-
tionship between clinical disease activity and HRQOL. It
seems that the relationship between clinical disease activ-
ity and HRQOL is not a direct relationship as such.
Only in the UC/IBD-U group, gender, age, and dis-
ease duration were significantly associated with HRQOL,
even after adding the psychological factors to the model.
For gender, previous studies in youth with IBD did not
find an association with HRQOL [66–68]. These studies
all included both CD and UC patients, but the majority
of youth had CD (> 70%), which may have masked the
association between gender and HRQOL in the UC pa-
tients. However, it remains unclear what role gender has
in affecting HRQOL, especially since gender is associat-
ed with more anxiety and depressive symptoms in gen-
eral [69], as well as in our own cohort [31]. Anxiety and
depressive symptoms are known to affect HRQOL in
youth with IBD [21, 64]. For age, our results indicated
that older age was associated with lower HRQOL in
youth with UC/IBD-U. This is accordance with Otley
et al. [68], who also reported that older age was associ-
ated with lower HRQOL in the first year after diagnosis
of IBD. However, in their sample, a large majority of
youth was diagnosed with CD (77%). Other studies did
not find association between age and HRQOL [30, 70] or
the reversed association (lower HRQOL in younger pa-
tients; [20]). These mixed findings were confirmed in a
review on predictors of HRQOL in youth with IBD [6].
Finally, in our study, a shorter disease duration was as-
sociated with a lower HRQOL in youth with UC/IBD-U.
Previous studies have suggested that it seems that disease
duration is not associated with HRQOL in general, but
only within the first months after diagnosis (of both CD
and UC/IBD-U) [30, 68]. However, these studies includ-
ed mainly CD patients (77% and 100%, respectively)
[30, 68]. In our sample, only 20% had a disease duration
of 6 months or shorter. Therefore, our results suggest
that for youth with CD in the first 6 months after the
diagnosis, disease duration is not associated with
HRQOL. For UC and IBD-U, this relationship is unclear
less clear defined. Although these differences between
the disease groups are important to notice, the most im-
portant finding remains that, overall, in both disease
groups, illness perceptions and depression were signifi-
cantly associated with HRQOL.
Strengths
Our sample (N = 262) is one of the largest European sam-
ples and innovative in studying the influence of both dis-
ease, demographic, and psychological factors in youth
with IBD. Our large sample covers a broad age range,
using internationally validated and age-attuned instru-
ments. This age range is an important life phase, as sev-
eral biological and psychosocial changes take place, and a
chronic disease such as IBD can have negative conse-
quences for the transition to adulthood. In addition, our
sample was derived from 6 centers (both urban and rural
areas), making generalization of our findings stronger. In
addition, and contrary to other studies that only included
either anxiety or depression (e.g., [8, 11]), we assessed
both anxiety and depression, as this had implications for
subsequent psychological treatment. Most importantly,
whereas previous studies mostly examined individual re-
lationships between disease factors, psychological factors
and HRQOL, we aimed to test the influence of disease,
demographic, and psychological factors simultaneously.
An advantage of this approach is that the current study
took into account the interrelationships between all the
factors in their associations with HRQOL.
Limitations
The number of patients with active disease (mostly mild
clinical disease activity) was low (25%), although this
number is often found in population-based cohorts of
patients with IBD. It may be that the associations be-
tween the psychological variables and HRQOL are not
the same for patients that have more active disease.
Nevertheless, studies with a higher proportion of patients
with active disease reported similar results [6, 21, 64,
65]. However, despite these findings, it is still possible
that for patients with moderate to severe clinical disease
activity, the relationships between illness perceptions, de-
pression, and HRQOL are different. Since evidence has
been found for a negative impact of clinical disease ac-
tivity on anxiety, depression, and/or HRQOL (e.g., [11,
23]), even stronger relationships may be found in patient
populations with more active disease. Another limitation
is that our data were cross-sectional and conclusions on
causal relationships cannot be drawn. Longitudinal
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studies are needed to examine causal relationships over
time. Until now, only few studies have been conducted
that were able to draw conclusion on causal relation-
ships. For example, a recent study in adults with IBD
found evidence for a bidirectional and causal relationship
between disease activity and anxiety/depression [71].
However, such studies have not been conducted investi-
gating HRQOL. A last limitation is that we had a re-
sponse rate of approximately 70%, which can have
caused bias, for example, if patients with a lower
HRQOL were more inclined to participate than those
with higher HRQOL. However, we were not able to
compare the HRQOL of responders and nonresponders.
Clinical Implications
These results stress the importance of psychological fac-
tors for HRQOL in youth with IBD, over and above de-
mographic and disease variables. In our study sample,
75% of the patients were in clinical remission.
Therefore, treating (pediatric) gastroenterologists should
pay attention to these psychological factors, in all patients
and not only in patients with active disease. We recom-
mend screening for negative illness perceptions and inter-
nalizing problems. This can be done either during a med-
ical visit or using short (online) questionnaires prior to the
medical visit. Our results also have implications for psy-
chological treatment of these patients: interventions for
improving HRQOL should focus on negative illness per-
ceptions and depression and also on anxiety for youth
with UC/IBD-U. For example, cognitive behavioral ther-
apy (CBT) has been proven effective in using techniques
to restructure thoughts, such as negative illness percep-
tions [72]. Importantly, at the beginning of a psychologi-
cal intervention disproportionate, unrealistic or incorrect
thoughts and ideas should be identified. At this phase, it is
important to determine whether a patient has dispropor-
tionate or incorrect negative illness perceptions. These can
then be crucial when practicing cognitive and behavioral
techniques. Naturally, the techniques of CBT can be used
to improve depression and anxiety as well [73, 74].
In conclusion, our study found that negative illness percep-
tions and depression are negatively associated with HRQOL
in youth with IBD, even after controlling for several demo-
graphic and disease factors, with also other psychological fac-
tors (i.e., coping, anxiety) taken into account. These factors
seriously influence HRQOL, even in our cohort with low clin-
ical disease activity, and should be considered by the medical
team. Our results indicate that, irrespective of the clinical dis-
ease activity, psychological treatment should focus on the way
these young IBD patients perceive their disease and on their
depressive symptoms. For youth with UC and IBD-U, anxiety
and worries should receive attention as well.
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